RK

Ramasamy Kavitha

Director Director DIN 08082258
DIN 08082258 First appointment May 2019 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Past companies 2 historical roles
Total affiliations 2 Since May 2019
Shareholding value β€’β€’β€’β€’ Premium profile

About Ramasamy Kavitha

Data last updated:

Ramasamy Kavitha was a Director at Medigrand Pharmaceuticals Private Limited (2019–2020) and Additional Director at Blured Pharmaceuticals Private Limited (2019). The companies operate in Pharma.

DIN 08082258
Primary Designation Director
Industry Pharma
First Appointment 31 May 2019

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director29 Jul 20192011₹1.34 Cr (FY 2022)Active
Additional Director31 May 20192015₹2.87 Cr (FY 2024)Active

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Medigrand Pharmaceuticals Private Limited
Blured Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Ramasamy Kavitha

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Ramasamy Kavitha

Ramasamy Kavitha was first appointed on 31 May 2019 as Additional Director at Blured Pharmaceuticals Private Limited.

Ramasamy Kavitha held 2 earlier board appointments: Medigrand Pharmaceuticals Private Limited (Director, 29 Jul 2019 to 16 Dec 2020); Blured Pharmaceuticals Private Limited (Additional Director, 31 May 2019 to 30 Sep 2019).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available